Eli Lilly

Eli Lilly and Company is a publicly traded pharmaceutical company (NYSE: LLY) and, by market value, one of the largest in the world, propelled in recent years by its metabolic and obesity franchises. It appears here for two reasons. First, like Moderna, Lilly is a heavy AI adopter, applying machine learning across drug discovery, clinical development, and operations. Second — and more distinctively — Lilly has productized its internal AI: through TuneLab, it offers external biotech companies access to AI models (for small-molecule and antibody work) trained on Lilly's own proprietary, decades-deep datasets, delivered via privacy-preserving federated learning so partners benefit without Lilly exposing the underlying data.

That makes Lilly an unusual and instructive case: a pharma incumbent that turned an internal AI capability into an outward-facing platform (TuneLab has its own catalogued page). The honest investment framing is that Lilly's value rests overwhelmingly on its drug pipeline and commercial franchises, not on AI as a product line — AI is an efficiency and partnership lever layered on top. For learners, Lilly is the clearest example of the "productized adopter": a company that both uses AI internally at scale and, selectively, sells access to what it has built.